Table Graph
      published meta-analysis   sensitivity analysis   studies

mRNA vaccine in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 6 months symptomatic COVIDdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.09 [0.07; 0.11] 0.09[0.07; 0.11]BNT162b2 phase 3 (C4591001, Polack), 202010%46,077NAnot evaluable confirmed Covid-19, from 1st dosedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] COVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09] Tang, 2021 0.16 [0.10; 0.25] 0.12[0.06; 0.23]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, Tang, 2021386%75,996lownot evaluable death D28detailed resultsHusby (Moderna), 2021 0.41 [0.37; 0.46] 0.41[0.37; 0.46]Husby (Moderna), 202110%NAnot evaluable deathsdetailed resultsBernal, 0 0.31 [0.14; 0.69] BNT162b2 phase 3 (C4591001, Polack), 2020 0.50 [0.09; 2.73] COVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84] Goldberg, 2021 0.06 [0.05; 0.07] Haas, 2021 0.03 [0.03; 0.04] Lauring, 2022 0.51 [0.20; 1.30] 0.14[0.07; 0.29]Bernal, 0, BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, Goldberg, 2021, Haas, 2021, Lauring, 2022693%72,519NAnot evaluable vaccine efficacy from randomization (ITT)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] COVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11] 0.11[0.04; 0.29]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020291%71,720moderatenot evaluable confirmed COVID (any severity)detailed resultsBernal (PHE, 19th February 2021), 2021 0.39 [0.31; 0.49] Bjork, 2021 0.14 [0.06; 0.30] Butt, 2021 0.04 [0.03; 0.05] England (Andrews), 2021 0.51 [0.35; 0.76] Heymann, 2021 0.11 [0.06; 0.19] South Africa (Discovery Health, Collie), 2021 0.50 [0.38; 0.65] Southern California (Tseng) - delta, 2022 0.05 [0.04; 0.06] Southern California (Tseng) - omicron, 2022 0.70 [0.51; 0.95] Tartof, 2021 0.27 [0.26; 0.28] Tenforde, 2022 0.18 [0.14; 0.23] Thompson, 2021 0.10 [0.03; 0.33] Thompson -VISIOn Network (omicron), 2022 0.48 [0.42; 0.54] 0.21[0.13; 0.33]Bernal (PHE, 19th February 2021), 2021, Bjork, 2021, Butt, 2021, England (Andrews), 2021, Heymann, 2021, South Africa (Discovery Health, Collie), 2021, Southern California (Tseng) - delta, 2022, Southern California (Tseng) - omicron, 2022, Tartof, 2021, Tenforde, 2022, Thompson, 2021, Thompson -VISIOn Network (omicron), 20221298%246,825NAlow death or ventilationdetailed resultsLauring, 2022 0.56 [0.46; 0.68] 0.56[0.46; 0.68]Lauring, 202210%11,690NAnot evaluable hospitalizationdetailed resultsDagan, 2021 0.13 [0.00; Infinity] Goldberg, 2021 0.06 [0.05; 0.06] Haas, 2021 0.03 [0.02; 0.03] Lauring, 2022 0.15 [0.13; 0.17] Mayo Clinic (Puranik), 2021 0.19 [0.04; 0.81] South Africa (Discovery Health, Collie), 2021 0.30 [0.24; 0.38] Tartof, 2021 0.10 [0.09; 0.12] Tenforde, 2021 0.16 [0.12; 0.22] Thompson -VISIOn Network (omicron), 2022 0.19 [0.10; 0.36] 0.11[0.06; 0.20]Dagan, 2021, Goldberg, 2021, Haas, 2021, Lauring, 2022, Mayo Clinic (Puranik), 2021, South Africa (Discovery Health, Collie), 2021, Tartof, 2021, Tenforde, 2021, Thompson -VISIOn Network (omicron), 2022999%1,253,843lownot evaluable symptomatic Covid-19detailed resultsAndrejko, 2021 0.13 [0.05; 0.32] Angel, 2021 0.03 [0.01; 0.07] BNT162b2 phase 3 (C4591001, Polack), 2020 0.05 [0.02; 0.10] Canada (Nasreen), 2021 0.11 [0.09; 0.14] Chung, 2021 0.09 [0.07; 0.12] COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11] Dagan, 2021 0.06 [0.02; 0.15] England (Andrews), 2021 0.51 [0.35; 0.76] Haas, 2021 0.03 [0.03; 0.03] Kirsebom (UKHSA), 2022 0.83 [0.81; 0.85] Mayo Clinic (Puranik), 2021 0.24 [0.13; 0.43] Nanduri, 2021 0.48 [0.44; 0.52] Oxford (Pouwels), 2021 0.16 [0.14; 0.18] Public Health England, May 16, 2021 (Bernal), 2021 0.06 [0.05; 0.08] Qatar (Tang), 2021 0.47 [0.39; 0.56] Scotland delta (Sheikh), 2021 0.17 [0.13; 0.22] South Africa (Discovery Health, Collie), 2021 0.50 [0.38; 0.65] Tang, 2021 0.00 [0.00; 0.05] Thompson -VISIOn Network (omicron), 2022 0.48 [0.42; 0.54] 0.14[0.07; 0.27]Andrejko, 2021, Angel, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, Canada (Nasreen), 2021, Chung, 2021, COVE Moderna/NIH phase 3 (study 301), 2020, Dagan, 2021, England (Andrews), 2021, Haas, 2021, Kirsebom (UKHSA), 2022, Mayo Clinic (Puranik), 2021, Nanduri, 2021, Oxford (Pouwels), 2021, Public Health England, May 16, 2021 (Bernal), 2021, Qatar (Tang), 2021, Scotland delta (Sheikh), 2021, South Africa (Discovery Health, Collie), 2021, Tang, 2021, Thompson -VISIOn Network (omicron), 202219100%1,913,200lowcritical 6 months severe COVID-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.03 [0.00; 0.46] 0.03[0.00; 0.46]BNT162b2 phase 3 (C4591001, Polack), 202010%NAnot evaluable asymptomatic COVID casedetailed resultsAngel, 2021 0.14 [0.07; 0.29] Haas, 2021 0.09 [0.08; 0.09] Tang, 2021 0.28 [0.18; 0.43] Weekes, 2021 0.25 [0.09; 0.72] 0.16[0.08; 0.35]Angel, 2021, Haas, 2021, Tang, 2021, Weekes, 2021491%16,732NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsAmit, 2021 0.25 [0.19; 0.33] Bjork, 2021 0.14 [0.06; 0.30] Cavanaugh, 2021 0.38 [0.19; 0.76] Dagan, 2021 0.08 [0.05; 0.12] Goldberg, 2021 0.07 [0.07; 0.07] Heymann, 2021 0.11 [0.06; 0.19] Oxford (Pouwels), 2021 0.20 [0.17; 0.23] Scotland delta (Sheikh), 2021 0.21 [0.18; 0.25] SIREN (HW england), 2021 0.15 [0.06; 0.38] Tang, 2021 0.21 [0.15; 0.29] Weekes, 2021 0.23 [0.11; 0.49] 0.16[0.10; 0.26]Amit, 2021, Bjork, 2021, Cavanaugh, 2021, Dagan, 2021, Goldberg, 2021, Heymann, 2021, Oxford (Pouwels), 2021, Scotland delta (Sheikh), 2021, SIREN (HW england), 2021, Tang, 2021, Weekes, 20211198%1,374,863lowcritical severe COVID-19 occurrencedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.25 [0.01; 5.62] Canada (Nasreen), 2021 0.05 [0.03; 0.08] Chung, 2021 0.02 [0.00; Infinity] COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27] Dagan, 2021 0.08 [0.00; Infinity] Goldberg, 2021 0.06 [0.05; 0.06] Grannis, 2021 0.20 [0.15; 0.27] Haas, 2021 0.03 [0.02; 0.03] Mayo Clinic (Puranik), 2021 0.19 [0.04; 0.81] Qatar (Tang), 2021 0.10 [0.02; 0.47] Tenforde, 2021 0.16 [0.12; 0.22] 0.08[0.04; 0.15]BNT162b2 phase 3 (C4591001, Polack), 2020, Canada (Nasreen), 2021, Chung, 2021, COVE Moderna/NIH phase 3 (study 301), 2020, Dagan, 2021, Goldberg, 2021, Grannis, 2021, Haas, 2021, Mayo Clinic (Puranik), 2021, Qatar (Tang), 2021, Tenforde, 20211196%1,324,250moderatelow transmission (symptomatic confirmed COVID19)detailed resultsHarris, 2021 0.54 [0.47; 0.62] Public Health England (Harris), 2021 0.51 [0.44; 0.59] 0.53[0.48; 0.58]Harris, 2021, Public Health England (Harris), 202120%seriousnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsAmit, 2021 0.15 [0.08; 0.29] BNT162b2 phase 3 (C4591001, Polack), 2020 0.48 [0.32; 0.71] Chodcik, 2021 0.49 [0.22; 1.07] Chung, 2021 0.40 [0.37; 0.44] Scotland cohort, 0 0.15 [0.09; 0.24] SIREN (HW england), 2021 0.30 [0.17; 0.52] Tang, 2021 0.42 [0.26; 0.69] Thompson, 2021 0.20 [0.10; 0.40] 0.30[0.22; 0.41]Amit, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, Chodcik, 2021, Chung, 2021, Scotland cohort, 0, SIREN (HW england), 2021, Tang, 2021, Thompson, 2021876%1,620,619lownot evaluable cerebrovascular thromboembolic eventsdetailed resultsBarda, 2021 0.84 [0.55; 1.29] 0.84[0.55; 1.29]Barda, 202110%NAnot evaluable related AE (TRAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.91 [4.58; 5.26] 4.91[4.58; 5.26]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable related SAE (TRSAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 8.00 [0.42; 151.43] 8.00[0.42; 151.43]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable serious adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.14 [0.88; 1.47] COVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40] 1.10[0.90; 1.33]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%73,603moderatenot evaluable acute kidney injury detailed resultsBarda, 2021 0.44 [0.25; 0.78] 0.44[0.25; 0.78]Barda, 202110%NAnot evaluable adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.62 [2.49; 2.76] COVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20] 1.73[0.77; 3.91]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 20202100%73,603moderatenot evaluable Anemia detailed resultsBarda, 2021 0.79 [0.67; 0.93] 0.79[0.67; 0.93]Barda, 202110%NAnot evaluable arrhythmiadetailed resultsBarda, 2021 0.89 [0.75; 1.06] 0.89[0.75; 1.06]Barda, 202110%NAnot evaluable Arthritis or arthropathy detailed resultsBarda, 2021 0.95 [0.66; 1.36] 0.95[0.66; 1.36]Barda, 202110%NAnot evaluable convulsions/seizures detailed resultsBarda, 2021 0.99 [0.61; 1.61] Klein, 2021 1.04 [0.84; 1.29] 1.03[0.85; 1.26]Barda, 2021, Klein, 202120%150criticalnot evaluable deep vein thrombosisdetailed resultsBarda, 2021 0.87 [0.55; 1.39] 0.87[0.55; 1.39]Barda, 202110%NAnot evaluable disseminated intravascular coagulation detailed resultsKlein, 2021 0.70 [0.39; 1.27] 0.70[0.39; 1.27]Klein, 202110%25NAnot evaluable Guillain-Barré syndrome detailed resultsKlein, 2021 0.70 [0.22; 2.27] Li X, 2022 0.79 [0.33; 1.90] Patone, 2021 0.86 [0.54; 1.36] 0.83[0.56; 1.22]Klein, 2021, Li X, 2022, Patone, 202130%6NAnot evaluable Herpes simplex infection detailed resultsBarda, 2021 1.13 [0.94; 1.36] 1.13[0.94; 1.36]Barda, 202110%NAnot evaluable herpes zoster infection detailed resultsBarda, 2021 1.43 [1.19; 1.72] Shasha, 2021 1.07 [0.85; 1.35] 1.25[0.94; 1.66]Barda, 2021, Shasha, 2021273%moderatenot evaluable immune thrombocytopenia detailed resultsKlein, 2021 2.60 [0.39; 17.24] 2.60[0.39; 17.24]Klein, 202110%2NAnot evaluable intracranial hemorrhage detailed resultsBarda, 2021 0.48 [0.23; 1.01] Patone, 2021 1.24 [1.07; 1.43] 0.83[0.33; 2.08]Barda, 2021, Patone, 2021283%moderatenot evaluable ischemic strokedetailed resultsEPI-PHARE, 2021 0.99 [0.84; 1.16] Klein, 2021 0.97 [0.87; 1.08] 0.98[0.89; 1.07]EPI-PHARE, 2021, Klein, 202120%650criticalnot evaluable life-threatening SAEdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.91 [0.51; 1.65] 0.91[0.51; 1.65]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable Myocardial infarction detailed resultsBarda, 2021 1.07 [0.73; 1.57] EPI-PHARE, 2021 1.07 [0.88; 1.31] Klein, 2021 1.02 [0.89; 1.17] 1.04[0.93; 1.16]Barda, 2021, EPI-PHARE, 2021, Klein, 202130%375criticalnot evaluable myocarditisdetailed resultsBarda, 2021 3.24 [1.14; 9.18] Husby (Moderna), 2021 3.92 [2.30; 6.68] Husby (pfizer), 2021 1.34 [0.90; 2.00] Klein, 2021 1.18 [0.78; 1.78] 1.98[1.09; 3.60]Barda, 2021, Husby (Moderna), 2021, Husby (pfizer), 2021, Klein, 2021480%39moderatenot evaluable neutropenia detailed resultsBarda, 2021 0.87 [0.46; 1.65] 0.87[0.46; 1.65]Barda, 202110%NAnot evaluable paresthesia detailed resultsBarda, 2021 1.12 [1.00; 1.26] Shasha, 2021 1.22 [1.11; 1.34] 1.18[1.09; 1.28]Barda, 2021, Shasha, 2021220%moderatenot evaluable pericarditis detailed resultsBarda, 2021 1.27 [0.69; 2.34] Klein, 2021 1.18 [0.78; 1.78] 1.21[0.86; 1.70]Barda, 2021, Klein, 202120%39criticalnot evaluable pulmonary embolismdetailed resultsBarda, 2021 0.56 [0.24; 1.31] EPI-PHARE, 2021 1.15 [0.90; 1.46] Klein, 2021 1.01 [0.86; 1.19] 1.03[0.86; 1.24]Barda, 2021, EPI-PHARE, 2021, Klein, 2021329%290criticalnot evaluable severe adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.74 [1.41; 2.14] 1.74[1.41; 2.14]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable thrombocytopenia detailed resultsBarda, 2021 0.94 [0.66; 1.33] 0.94[0.66; 1.33]Barda, 202110%NAnot evaluable Transverse myelitis detailed resultsKlein, 2021 1.45 [0.07; 31.68] 1.45[0.07; 31.68]Klein, 202110%1NAnot evaluable uveitis detailed resultsBarda, 2021 1.27 [0.64; 2.52] 1.27[0.64; 2.52]Barda, 202110%NAnot evaluable venous thromboembolism detailed resultsKlein, 2021 1.16 [1.00; 1.34] 1.16[1.00; 1.34]Klein, 202110%327NAnot evaluable VTE with thrombocytopeniadetailed resultsKlein, 2021 0.86 [0.58; 1.27] 0.86[0.58; 1.27]Klein, 202110%53NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsKlein, 2021 1.55 [0.33; 7.28] McMurry, 2021 0.50 [0.02; 14.82] Pawlowski, 2021 1.50 [0.30; 7.55] 1.37[0.47; 3.95]Klein, 2021, McMurry, 2021, Pawlowski, 202130%686,456moderatenot evaluable appendicitisdetailed resultsBarda, 2021 1.40 [1.00; 1.97] BNT162b2 phase 3 (C4591001, Polack), 2020 2.00 [0.60; 6.65] COVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99] Klein, 2021 0.82 [0.73; 0.93] 1.09[0.69; 1.72]Barda, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, Klein, 2021471%74,290criticalnot evaluable arthralgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91] 18.37[13.54; 24.91]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable Bell's palsydetailed resultsBarda, 2021 1.32 [0.93; 1.88] BNT162b2 phase 3 (C4591001, Polack), 2020 7.99 [0.42; 151.24] COVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83] Klein, 2021 1.00 [0.86; 1.17] Li X, 2022 0.83 [0.62; 1.11] McMurry, 2021 0.40 [0.21; 0.78] Patone, 2021 1.06 [0.90; 1.25] Shasha, 2021 0.96 [0.54; 1.70] Shemer, 2021 0.84 [0.37; 1.90] Shibli, 2021 1.36 [1.14; 1.62] Wan, 2021 1.75 [0.89; 3.48] 1.06[0.89; 1.26]Barda, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, Klein, 2021, Li X, 2022, McMurry, 2021, Patone, 2021, Shasha, 2021, Shemer, 2021, Shibli, 2021, Wan, 20211161%68,238lowlow hypersensitivity, all termsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.17 [0.82; 5.71] COVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72] 1.43[1.18; 1.74]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%73,603moderatenot evaluable immediate allergic reactiondetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.00 [0.02; 50.42] 1.00[0.02; 50.42]BNT162b2 phase 3 (C4591001, Polack), 202010%43,448NAnot evaluable lymphadenopathy, anydetailed resultsBarda, 2021 2.43 [2.09; 2.83] BNT162b2 phase 3 (C4591001, Polack), 2020 10.69 [4.63; 24.69] 4.80[1.13; 20.41]Barda, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020291%37,586seriousnot evaluable lymphadenopathy, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 3.65 [3.26; 4.09] COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 3.64[3.25; 4.08]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%67,937moderatenot evaluable myalgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50] 27.64[20.93; 36.50]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable myelitisdetailed resultsLi X, 2022 0.77 [0.40; 1.48] Patone, 2021 1.14 [0.86; 1.51] 1.05[0.77; 1.43]Li X, 2022, Patone, 2021214%NAnot evaluable fever, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10] 43.29[17.83; 105.10]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable local adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 24.90 [22.13; 28.03] 24.90[22.13; 28.03]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable local adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 23.04 [20.30; 26.15] COVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03] 27.99[19.26; 40.68]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020296%36,742moderatenot evaluable local adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12] 15.04[11.83; 19.12]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable systemic adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.63 [1.50; 1.78] 1.63[1.50; 1.78]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.55 [4.13; 5.01] COVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05] 5.53[3.79; 8.06]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020298%36,749moderatenot evaluable systemic adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77] 9.50[8.38; 10.77]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable serologic response (seroconversion)detailed resultsGrupper, 2021 0.01 [0.00; 0.21] Monin, 2021 0.78 [0.02; 25.26] 0.09[0.00; 5.02]Grupper, 2021, Monin, 2021270%192NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-05-13 07:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 806,758,826,755 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons